ArticleMaterials today. Bio2026
Hypoxia-programmed apoptotic-mimetic M2 macrophage-derived small extracellular vesicles for hydrogel-mediated immunoregenerative bone repair.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective regeneration of critical-sized bone defects requires the coordinated reconstruction of immune homeostasis, vascular networks, and osteogenic matrix formation. However, conventional bone-regenerative materials frequently provide structural support or single-pathway osteoinduction, while failing to actively orchestrate the multicellular repair microenvironment. Here, we develop a hydrogel-assisted immunoregenerative strategy based on hypoxia-programmed apoptotic-mimetic small extracellular vesicles derived from M2-like macrophages. Interleukin-4-polarized macrophages were subjected to hypoxic preconditioning to generate M2-HP-Apo-sEVs with increased phosphatidylserine exposure, enhanced cellular internalization, and amplified immunomodulatory potency. Compared with normoxic M2-sEVs, M2-HP-Apo-sEVs more effectively reprogrammed inflammatory macrophages toward a pro-resolving phenotype, suppressed inflammatory cytokine production, and enhanced reparative cytokine secretion. The vesicles further promoted osteogenic differentiation of bone marrow mesenchymal stem cells and stimulated endothelial migration and capillary-like network formation, demonstrating coordinated osteo-immuno-angiogenic activity. To enable sustained local delivery, M2-HP-Apo-sEVs were incorporated into photocrosslinkable GelMA hydrogels and implanted into critical-sized calvarial defects. The GelMA-M2-HP-Apo-sEV system substantially enhanced bone regeneration, vascularization, and osteogenic matrix deposition while attenuating local inflammation. This work establishes a cell-free vesicle-hydrogel platform that integrates donor-cell hypoxic programming, apoptotic-mimetic membrane signaling, and local biomaterial delivery for immunoregenerative bone repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.